This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 28/8/1511    most recent ATVBAHA.108.168021v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montezano, A.C. Articles by Touyz, R.M. Search for Related Content PubMed PubMed Citation Articles by Montezano, A.C. Articles by Touyz, R.M.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1511.)
© 2008 American Heart Association, Inc.

Cell Biology/Signaling

Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways

A.C. Montezano; G.E. Callera; A. Yogi; Y. He; R.C. Tostes; G. He; E.L. Schiffrin; R.M. Touyz

From the Ottawa Health Research Institute (A.C.M., G.E.C., A.Y., Y.H., G.H., R.M.T.), Kidney Research Centre, University of Ottawa, Ontario, Canada; the Institute of Biomedical Sciences (A.Y., R.C.T.), University of Sao Paulo, Brazil; and Lady Davis Institute (E.L.S.), McGill University, Montreal, Quebec, Canada.

Correspondence to Rhian M Touyz, MD, PhD, Kidney Research Centre, OHRI/University of Ottawa, 451 Smyth Road, Ottawa, K1H 8M5, Ontario, Canada. E-mail rtouyz{at}uottawa.ca

Objective— Synergistic interactions between aldosterone (Aldo) and angiotensin II (Ang II) have been implicated in vascular inflammation, fibrosis, and remodeling. Molecular mechanisms underlying this are unclear. We tested the hypothesis that c-Src activation, through receptor tyrosine kinase transactivation, is critically involved in synergistic interactions between Aldo and Ang II and that it is upstream of promigratory signaling pathways in vascular smooth muscle cells (VSMCs).

Methods and Results— VSMCs from WKY rats were studied. At low concentrations (10^–10 mol/L) Aldo and Ang II alone did not influence c-Src activation, whereas in combination they rapidly increased phosphorylation (P<0.01), an effect blocked by eplerenone (Aldo receptor antagonist) and irbesartan (AT1R blocker). This synergism was attenuated by AG1478 and AG1296 (inhibitors of EGFR and PDGFR, respectively), but not by AG1024 (IGFR inhibitor). Aldo and Ang II costimulation induced c-Src-dependent activation of NAD(P)H oxidase and c-Src-independent activation of ERK1/2 (P<0.05), without effect on ERK5, p38MAPK, or JNK. Aldo/Ang II synergistically activated RhoA/Rho kinase and VSMC migration, effects blocked by PP2, apocynin, and fasudil, inhibitors of c-Src, NADPH oxidase, and Rho kinase, respectively.

Conclusions— Aldo/Ang II synergistically activate c-Src, an immediate signaling response, through EGFR and PDGFR, but not IGFR transactivation. This is associated with activation of redox-regulated RhoA/Rho kinase, which controls VSMC migration. Although Aldo and Ang II interact to stimulate ERK1/2, such effects are c-Src-independent. These findings indicate differential signaling in Aldo-Ang II crosstalk and highlight the importance of c-Src in redox-sensitive RhoA, but not ERK1/2 signaling. Blockade of Aldo/Ang II may be therapeutically useful in vascular remodeling associated with abnormal VSMC migration.

We questioned whether synergism between aldosterone and Ang II involves c-Src in vascular smooth muscle cells (VSMCs). Findings show that Aldo/Ang II synergistically phosphorylate c-Src through EGFR and PDGF transactivation, an effect associated with activation of redox-regulated RhoA/Rho kinase-mediated VSMC migration. Our findings highlight the importance of c-Src in redox-sensitive RhoA, but not ERK1/2 signaling. Aldo/Ang II blockade may be useful in treating vascular remodeling associated with abnormal VSMC migration.

Key Words: aldosterone • angiotensin II • c-Src • Rho A • synergism

This article has been cited by other articles:

				K. Ishizawa, Y. Izawa-Ishizawa, N. Dorjsuren, E. Miki, Y. Kihira, Y. Ikeda, S. Hamano, K. Kawazoe, K. Minakuchi, S. Tomita, et al. Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner Nephrol. Dial. Transplant., November 4, 2009; (2009) gfp520v2. [Abstract] [Full Text] [PDF]

				C. A. Lemarie, S. M.C. Simeone, A. Nikonova, T. Ebrahimian, M.-E. Deschenes, T. M. Coffman, P. Paradis, and E. L. Schiffrin Aldosterone-Induced Activation of Signaling Pathways Requires Activity of Angiotensin Type 1a Receptors Circ. Res., October 23, 2009; 105(9): 852 - 859. [Abstract] [Full Text] [PDF]

				G. Jain, R. C. Campbell, and D. G. Warnock Mineralocorticoid Receptor Blockers and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1685 - 1691. [Abstract] [Full Text] [PDF]

				Y. Minoura, H. Onimaru, K. Iigaya, I. Homma, and Y. Kobayashi Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R699 - R706. [Abstract] [Full Text] [PDF]

				B. Pitt RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice Heart, August 1, 2009; 95(15): 1205 - 1208. [Full Text] [PDF]

				J.-K. Park, S. Theuer, T. Kirsch, C. Lindschau, U. Klinge, A. Heuser, R. Plehm, M. Todiras, P. Carmeliet, H. Haller, et al. Growth Arrest Specific Protein 6 Participates in DOCA-Induced Target-Organ Damage Hypertension, August 1, 2009; 54(2): 359 - 364. [Abstract] [Full Text] [PDF]

				A. N. Lyle, N. N. Deshpande, Y. Taniyama, B. Seidel-Rogol, L. Pounkova, P. Du, C. Papaharalambus, B. Lassegue, and K. K. Griendling Poldip2, a Novel Regulator of Nox4 and Cytoskeletal Integrity in Vascular Smooth Muscle Cells Circ. Res., July 31, 2009; 105(3): 249 - 259. [Abstract] [Full Text] [PDF]

				A. Whaley-Connell, J. Habibi, Y. Wei, A. Gutweiler, J. Jellison, C. E. Wiedmeyer, C. M. Ferrario, and J. R. Sowers Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1013 - F1022. [Abstract] [Full Text] [PDF]

				E. Ritz How Little Aldosterone is Able to Raise Blood Pressure? Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 703 - 710. [Full Text] [PDF]

				B. Pitt Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction Eur. Heart J., February 3, 2009; (2009) ehp026v1. [Full Text] [PDF]

				Y. Wei, A. T. Whaley-Connell, J. Habibi, J. Rehmer, N. Rehmer, K. Patel, M. Hayden, V. DeMarco, C. M. Ferrario, J. A. Ibdah, et al. Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation Hypertension, February 1, 2009; 53(2): 158 - 165. [Abstract] [Full Text] [PDF]

				R. M. Touyz and G. E. Callera A New Look at the Eye: Aldosterone and Mineralocorticoid Receptors As Novel Targets in Retinal Vasculopathy Circ. Res., January 2, 2009; 104(1): 9 - 11. [Full Text] [PDF]

				A. C. Montezano and R. M. Touyz Networking Between Systemic Angiotensin II and Cardiac Mineralocorticoid Receptors Hypertension, December 1, 2008; 52(6): 1016 - 1018. [Full Text] [PDF]

				B. Pitt The measurement of plasma aldosterone in patients post-myocardial infarction Eur. Heart J., October 2, 2008; 29(20): 2451 - 2452. [Full Text] [PDF]

				A. K. Nagaraja, C. Andreu-Vieyra, H. L. Franco, L. Ma, R. Chen, D. Y. Han, H. Zhu, J. E. Agno, P. H. Gunaratne, F. J. DeMayo, et al. Deletion of Dicer in Somatic Cells of the Female Reproductive Tract Causes Sterility Mol. Endocrinol., October 1, 2008; 22(10): 2336 - 2352. [Abstract] [Full Text] [PDF]